Blood–brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody

2014152 citationsReview

Authors

William M. Pardridge · ArmaGen (United States)

Abstract

The BBB delivery of biologic drugs is possible following re-engineering as a fusion protein with a molecular Trojan horse such as a TfRMAb. The efficacy of this technology will be determined by the outcome of future clinical trials.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research Protein purification and stability RNA Interference and Gene Delivery

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Expert Opinion on Drug Delivery

Volume 12, Issue 2, pp. 207-222

DOI: 10.1517/17425247.2014.952627

Field-Weighted Citation Impact: 10.97